Results filed 4 November 2026 · Market cap ₹20,249 crore · PE 22.6
GrowthGuidance raisedTranscript read
Revenue
+36.3%
on a year ago
EBITDA
+78.4%
on a year ago
Profit to shareholders
+81.5%
on a year ago
EBITDA margin
21.6%
+6.2 pts on last quarter
Alembic reported a strong Q2 FY27 with consolidated revenue rising 36% YoY to ₹2,603 crore and EBITDA margins expanding 520 bps to 22.2%. Growth was spearheaded by US Generics (up 72% YoY, supported by base volume growth and the bosutinib exclusivity) and API sales (up 39% YoY). Reflecting first-half outperformance, management upgraded full-year revenue growth guidance to 20-25%, while acknowledging that exclusivity benefits will normalize starting Q3 FY27.
Source: Alembic Pharmaceuticals Limited’s filing to NSE, 4 November 2026. Operating profit is revenue less every expense except interest, so it leaves out other income and exceptional items. n.m.: not meaningful, because the earlier figure was zero or negative, or the latest one is a loss.
What stood out
Consolidated revenue grew 36% YoY to ₹2,603 crore, driven by exceptional 72% (77% in formulation reporting) growth in US Generics and 39% growth in API.SourceTranscript original page 3, Pranav Amin: 'Consolidated revenue for the quarter was at INR2,603 crores, representing a growth of 36% Y-on-Y... U.S. Generics delivered an exceptional quarter with revenue growing at 72% year-on-year'; Presentation original page 5.
EBITDA margin expanded by 520 bps YoY to 22.2% (reported EBITDA ₹5.78 bn), led by high-margin US launches such as bosutinib and operating leverage.SourcePresentation original page 4, 'EBITDA Margin +520 bps ₹5.78 bn; +78% YoY'; Transcript original page 5, G. Krishnan.
Exclusivity on bosutinib drives significant outperformance in the US, but exclusivity expires at the end of November 2026.SourceTranscript original page 6, Pranav Amin: 'So bosutinib has done, yes, far higher than expectations... we have exclusivity till end of November. So we've got 2 more months... What happens after that, I don't know.'
Guidance
Metric
Guidance
Period
Consolidated Revenue GrowthSourceTranscript original page 5, Pranav Amin: 'we are raising our FY27 consolidated revenue growth guidance to about 20% to 25% from the mid-teens indicated last quarter.'
20% to 25% YoY (raised from mid-teens)
FY27
US Business Revenue GrowthSourceTranscript original page 5, Pranav Amin: 'We now expect the U.S. business to grow up to 40% Y-on-Y for the full year...'
Up to 40% YoY
FY27
API Business Revenue GrowthSourceTranscript original page 5, Pranav Amin: 'API business has also performed ahead of our expectations and is now expected to deliver at least high teens growth for the year.'
At least high-teens growth
FY27
EBITDA MarginSourceTranscript original page 7, G. Krishnan: 'for the first half, we have about 22% EBITDA margins, which we expect to continue towards the second half as well. So we should expect the margin profile to hold for the rest of the year.'
~22% in H2 FY27, holding first half margin profile
FY27
Gross MarginSourceTranscript original page 5, 8, 14, G. Krishnan.
70% to 75%
FY27 and onward
US Business FY28 GrowthSourceTranscript original page 13, Pranav Amin: 'I think it will be close to mid like about 10% to 12% kind of a growth definitely we can see next year if all these launches pan out well.'
10% to 12% YoY
FY28
Consolidated revenue growth guidance upgraded from mid-teens to 20%-25% on the back of stronger US and API performance.
Tailwinds
US base portfolio volume growth and launch contributionsSourceTranscript original page 4 & 6, Pranav Amin: 'While the new launches, including bosutinib, provided an important uplift, the underlying business also demonstrated healthy operating momentum, growing at 23%.'
India Human Health rebound and chronic outperformanceSourceTranscript original page 3, Pranav Amin: 'led by the Human Health, which returned to double-digit growth at 11%... The specialty portfolio grew about 200 basis points ahead of the Indian pharmaceutical market'; Presentation original page 6.
API business volume expansion and CMO suppliesSourceTranscript original page 4, Pranav Amin: 'API business... sustained a strong growth trajectory and delivered volume-led growth of 39% Y-on-Y, which includes certain CMO deliveries to its key customers'.
Strong momentum in Animal Health businessSourcePresentation original page 8, Animal Health Revenue Q2 FY27 grew 23% YoY to ₹1.69 bn; Transcript original page 3.
Headwinds
Acute portfolio underperformance in the domestic marketSourceTranscript original page 3 & 7, Pranav Amin: 'Acute, yes, there are still some issues, but we're quite confident that hopefully, acute would also get to IPM level... in the next couple of quarters.'
Near-term EBITDA margin dilution from US Branded commercial buildoutSourceTranscript original page 8, G. Krishnan: 'at the beginning of the year, we guided for a 150 to 200 basis points dilution in the U.S. branded business. So I think that still holds.'
Higher logistics, freight, and solvent costs due to global geopolitical volatilitySourceTranscript original page 5 & 7, G. Krishnan: 'benefiting from favorable product mix despite higher solvent costs and geopolitical headwinds... logistics cost related to shipments from India to U.S. and other markets... saw a year-on-year increase'.
Expanded strategic collaboration with DifGen Pharmaceuticals
Expected benefit
Access to over 20 differentiated complex generic products (transdermal patches, complex injectables, ophthalmics) with an aggregate US reference market of ~$5 billion and select FTF/day-1 opportunities, plus reserved US manufacturing capacity.
Risks
Regulatory approvals and execution risks; market dynamics post-launch.
Timeline
Revenue contributions expected to begin from FY28
Investment
Licensing profit-share model, described as capital-efficient without specified upfront capex
SourceTranscript original page 4, Pranav Amin: 'The expanded partnership gives us access to a differentiated portfolio of over 20 products across transdermal patches, complex injectables, ophthalmics... addresses an aggregate U.S. reference market of approximately $5 billion... Contributions are expected to begin from FY28...'
new business · Operational with 4 products (Pivya, Nuvessa, Nuvetest, etc.); sales force ramped to 30-35 reps (targeting 40-45)
US Branded business expansion via Alembic Therapeutics
Expected benefit
Scalable specialty franchise; targeted to reach breakeven by end of FY27 or H1 FY28 and eliminate the current 150-200 bps margin drag.
Operating cost drag of 150-200 bps on full-year consolidated margin
SourceTranscript original page 4, 10, 11; Pranav Amin and G. Krishnan.
Things to check
Impending revenue and margin cliff on sole exclusivity asset bosutinib ending in November 2026SourceTranscript original page 6, Pranav Amin: 'we have exclusivity till end of November... What happens after that, I don't know.'
Significant increase in trade receivables from ₹14.66 bn in March 2026 to ₹18.96 bn in September 2026, elongating working capital cyclesSourcePresentation original page 14 (Balance Sheet); Transcript original page 6, G. Krishnan: 'The current working capital is largely linked to longer collection cycles, especially on the new U.S. launches...'
How the call went
The call offered helpful operational color and upgraded annual top-line targets, though management appropriately shielded granular commercial data around individual exclusivity assets.
Specific or vague
Management provided clear segment growth figures, base US growth ex-bosutinib (23%), and full-year margin outlook, but declined to disclose individual product sales numbers or volume/pricing splits quantitatively.
Candour
Management was open regarding the temporary nature of bosutinib exclusivity (expiring end of November 2026), persistent softness in the acute domestic portfolio, and the initial margin dilution from the US branded portfolio.
The hard questions
Analysts probed deeply into the margin sustainability once bosutinib loses exclusivity, the quarterly sales drag from Pivya, and exact volume versus price realization splits in India.
What analysts pressed on
Drop in US profitability and revenues post the expiration of bosutinib exclusivity in November 2026.
The exact ramp-up speed, prescription numbers, and financial breakeven timing of Pivya and the US branded franchise.
Underperformance of the domestic acute formulations business relative to IPM.
Cost escalation seen across other operating expenses, logistics, and personnel.
Answers that sidestepped
Refusal to provide specific product potential and forecasts for pipeline launches Uptravi and Toviaz.
Deflection on providing precise quantitative split of domestic growth across price, volume, and new launches ('directionally... almost 50-50').
Declining to disclose prescription counts or specific revenue run rates for Pivya.
Numbers against the story
Management's narrative centered on broad-based structural growth and sustainable momentum across geographies. However, reported results reveal that a substantial part of the surge in Q2 margins (EBITDA margin jumping 520 bps YoY to 22.2%) and US growth (+72-77%) was heavily aided by the limited-competition exclusivity of bosutinib, which is slated to normalize post-November 2026.
Figures: the company’s results filing with NSE, linked under the table.
Notes written by gemini-3.8-flash from the documents above on 15 November 2026. They summarise what the company said and can contain mistakes: check the source passage before relying on a point. Not investment advice.